×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BTAI – bioxcel therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BTAI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
07:00 am
btai
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Neutral
Report
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
11/20
03:36 am
btai
Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones [Yahoo! Finance]
Low
Report
Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones [Yahoo! Finance]
11/12
08:19 am
btai
BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84 [Seeking Alpha]
Medium
Report
BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84 [Seeking Alpha]
11/12
07:00 am
btai
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
High
Report
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
10/24
11:38 am
btai
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
10/14
07:53 am
btai
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes [Yahoo! Finance]
Low
Report
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes [Yahoo! Finance]
10/14
07:00 am
btai
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
Low
Report
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
10/13
07:42 am
btai
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation [Yahoo! Finance]
Low
Report
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
07:00 am
BTAI
bioxcel therapeutics, inc.
MISS
Report
-14.5%
bioxcel therapeutics, inc.
8/12/2025
07:55 am
BTAI
bioxcel therapeutics, inc.
MISS
Report
-17.1%
bioxcel therapeutics, inc.
5/12/2025
07:00 am
BTAI
bioxcel therapeutics, inc.
BEAT
Report
-4.5%
bioxcel therapeutics, inc.
3/27/2025
07:00 am
BTAI
bioxcel therapeutics, inc.
BEAT
Report
7.4%
bioxcel therapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/12
05:05 pm
btai
Form ARS BioXcel Therapeutics, For: Dec 31
Medium
Report
Form ARS BioXcel Therapeutics, For: Dec 31
11/12
05:01 pm
btai
Form DEF 14A BioXcel Therapeutics, For: Dec 12
Medium
Report
Form DEF 14A BioXcel Therapeutics, For: Dec 12
11/12
09:01 am
btai
Form 10-Q BioXcel Therapeutics, For: Sep 30
Medium
Report
Form 10-Q BioXcel Therapeutics, For: Sep 30
11/12
07:11 am
btai
Form 8-K BioXcel Therapeutics, For: Nov 12
High
Report
Form 8-K BioXcel Therapeutics, For: Nov 12
11/10
08:01 am
btai
Form 8-K BioXcel Therapeutics, For: Nov 10
Low
Report
Form 8-K BioXcel Therapeutics, For: Nov 10
11/3
08:00 pm
btai
Form 4 BioXcel Therapeutics, For: Oct 31 Filed by: MACK DAVID J.
Low
Report
Form 4 BioXcel Therapeutics, For: Oct 31 Filed by: MACK DAVID J.
10/31
05:15 pm
btai
Form PRE 14A BioXcel Therapeutics, For: Dec 12
Medium
Report
Form PRE 14A BioXcel Therapeutics, For: Dec 12
10/30
07:16 am
btai
Form 8-K BioXcel Therapeutics, For: Oct 30
Medium
Report
Form 8-K BioXcel Therapeutics, For: Oct 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/31
BioXcel Therapeutics Inc (NASDAQ: BTAI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock.
40.3%
2/14 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at SunTrust Banks, Inc. to $150.00. They now have a "buy" rating on the stock. 19.3%
2/5 BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms 16.0%
8/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 14.4%
1/16 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at BMO Capital Markets to $26.00. They now have a "positive" rating on the stock. 14.4%
3/19 BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials 12.9%
4/28 Form 4 BioXcel Therapeutics, For: Jan 02 Filed by: Nandabalan Krishnan 10.7%
4/6 Form DEF 14A BioXcel Therapeutics, For: May 20 9.9%
2/26 BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences 9.7%
1/13 Form 8-K BioXcel Therapeutics, For: Jan 13 9.5%
2/14 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at SunTrust Banks, Inc. to $150.00. They now have a "buy" rating on the stock. 19.3%
2/5 BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms 16.0%
8/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 14.4%
1/16 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its price target raised by analysts at BMO Capital Markets to $26.00. They now have a "positive" rating on the stock. 14.4%
3/19 BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials 12.9%
4/28 Form 4 BioXcel Therapeutics, For: Jan 02 Filed by: Nandabalan Krishnan 10.7%
4/6 Form DEF 14A BioXcel Therapeutics, For: May 20 9.9%
2/26 BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences 9.7%
1/13 Form 8-K BioXcel Therapeutics, For: Jan 13 9.5%
TOP News Decliners
3/14
BioXcel Therapeutics Inc (NASDAQ: BTAI) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
-26.4%
9/25 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -23.5%
3/2 BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast -21.3%
5/12 BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.7%
2/19 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -14.5%
3/9 BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -10.3%
3/10 BioXcel Therapeutics (BTAI) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -9.3%
10/18 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.6%
5/9 BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference -8.3%
1/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $25.00. -8.1%
9/25 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -23.5%
3/2 BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast -21.3%
5/12 BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.7%
2/19 BioXcel Therapeutics Announces Proposed Public Offering of Common Stock -14.5%
3/9 BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -10.3%
3/10 BioXcel Therapeutics (BTAI) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -9.3%
10/18 BioXcel Therapeutics Inc (NASDAQ: BTAI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.6%
5/9 BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference -8.3%
1/8 BioXcel Therapeutics Inc (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock, up previously from $25.00. -8.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: